Quest Diagnostics (NYSE:DGX) updated its FY 2026 earnings guidance. The company provided EPS guidance of 11.250-11.350 for the period, compared to the consensus estimate of 11.190. The company also issued revenue guidance of $12.1 billion, compared to the consensus estimate of $12.0 billion.